# Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

> **NCT00133848** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 210 (—)

## Conditions studied

- Impetigo

## Interventions

- **DRUG:** SB-275833 ointment, 1%

## Key facts

- **NCT ID:** NCT00133848
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 210 (—)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133848, "Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00133848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*